
Peer reviewed version

Link to published version (if available): 10.1182/blood-2016-05-716092

Link to publication record in Explore Bristol Research

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via American Society of Hematology at http://www.bloodjournal.org/content/early/2016/07/19/blood-2016-05-716092/tab-article-info. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy

Kate Burley¹, Claire S Whyte², Sarah K Westbury¹, Mary Walker³, Kathleen E Stirrups⁴,⁵, Ernest Turro⁴,⁶, NIHR BioResource⁵, Oliver G Chapman⁷, Christopher Reilly-Stitt³, Nicola J Mutch², Andrew D Mumford¹

1. School of Clinical Sciences, University of Bristol, Bristol, UK.
2. Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
3. Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
4. Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
5. NIHR BioResource - Rare Diseases, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
7. Department of Haematology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Scientific category: Thrombosis and hemostasis

Running title: Thrombomodulin-associated fibrinolysis

Word count: main text 1199; abstract 184

Corresponding author: Dr Andrew D. Mumford, School of Clinical Sciences, University of Bristol, Level 7 Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom; Tel: +44 117 3423152; email: a.mumford@bristol.ac.uk
KEY POINTS

• Thrombomodulin (TM)-associated coagulopathy is a heritable bleeding disorder in which high plasma TM levels reduce thrombin generation

• High plasma TM levels also delay clot lysis by enhancing TM/thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor
ABSTRACT

Thrombomodulin-associated coagulopathy (TM-AC) is a newly recognised dominant bleeding disorder in which a p.Cys537Stop variant in the thrombomodulin (TM) gene THBD, results in high plasma TM levels and protein C-mediated suppression of thrombin generation. Thrombin in complex with TM also activates thrombin activatable fibrinolysis inhibitor (TAFI). However, the effect of the high plasma TM on fibrinolysis in TM-AC is unknown. Plasma from TM-AC cases and high-TM model control samples spiked with recombinant soluble TM showed reduced tissue factor-induced thrombin generation. Lysis of plasma clots from TM-AC cases was significantly delayed compared to controls, but was completely restored when TM/thrombin-mediated TAFI activation was inhibited. Clots formed in blood from TM-AC cases had the same viscoelastic strength as controls but also showed a TAFI-dependent delay in fibrinolysis. Delayed fibrinolysis was reproduced in high-TM model plasma and blood samples. Partial restoration of thrombin generation with rFVIIa or aPCC did not alter the delayed fibrinolysis in high-TM model blood. Our finding of a previously unrecognised fibrinolytic phenotype indicates that bleeding in TM-AC has a complex pathogenesis and highlights the pivotal role of TM as a regulator of haemostasis.
INTRODUCTION

Thrombomodulin (TM) is a type-1 transmembrane glycoprotein encoded by \textit{THBD} and expressed at high levels on vascular endothelial cells\textsuperscript{1}. TM binds thrombin with high affinity and changes its substrate specificity to favour protein C (PC), which when activated to APC down-regulates further thrombin generation by inactivating factors Va and VIIIa\textsuperscript{2,3}. Consistent with this down-regulatory role, reduced endothelial TM expression has been associated with disseminated intravascular coagulation\textsuperscript{4} and venous thrombosis\textsuperscript{5}. TM has also been linked to the pathogenesis of a dominant bleeding disorder caused by a \textit{THBD} variant predicting a p.Cys537Stop substitution in the TM transmembrane domain. This results in high plasma TM levels, consistent with shedding of TM extracellular domain from the endothelium\textsuperscript{6,7}. It has been proposed that abnormal bleeding in this disorder, hereafter termed TM-associated coagulopathy (TM-AC), results from enhanced TM-mediated APC generation and suppression of further thrombin generation\textsuperscript{6,7}.

In addition to mediating APC generation, TM in complex with thrombin is also a potent activator of thrombin-activatable fibrinolysis inhibitor (TAFI)\textsuperscript{8}. Activated TAFI (TAFIa) cleaves carboxyl-terminal lysine residues from the fibrin surface thereby reducing binding of plasminogen and tPA, and down-regulating fibrinolysis\textsuperscript{9,10}. Here we describe the impact of high plasma TM levels on TAFI-mediated clot lysis in an unreported pedigree with TM-AC and reveal a previously unrecognised fibrinolytic component of the TM-AC phenotype.
METHODS

Study cases and coagulation studies

The study cases were enrolled to the NIHR BioResource rare diseases (UK REC 13/EE/0325) after informed written consent, in accordance with the Declaration of Helsinki. Plasma TM concentration was measured by ELISA (Abcam, Cambridge, UK). Calibrated automated thrombography (CAT) was performed on platelet poor plasma with the PPP LOW reagent (1 pM tissue factor (TF) and a Fluoroscan fluorimeter (Thermo-Fisher, Basingstoke, UK)\textsuperscript{11}. Experiments were also performed in high-TM model blood or plasma using samples from healthy controls spiked with 250-2500 ng/ml recombinant C-terminal truncated TM (Peprotech, Hamburg, Germany). \textit{THBD} was analysed by whole genome sequencing through the BRIDGE-BPD project\textsuperscript{12} and the ThromboGenomics high-throughput platform\textsuperscript{13}.

Plasma fibrinolysis

Clots were formed in re-calcified, diluted plasma with 0.1 U/ml thrombin (Sigma-Aldrich, Poole, UK) as previously reported\textsuperscript{14} in the presence of 300 pM recombinant tissue plasminogen activator (tPA; Genentech, San Francisco, Ca) and 16 µM phospholipids (Rossix, Molndal, Sweden). Clots were formed in the absence or presence of 500 ng/ml TM, 25 µg/ml potato tuber carboxypeptidase inhibitor (PTCI; Sigma-Aldrich; a TAFIa inhibitor) or 65 µg/ml MA-T12D11 (a monoclonal antibody inhibitor of thrombin/TM-mediated TAFI activation\textsuperscript{15}). Turbidity was monitored every minute at 405 nm.

Whole blood fibrinolysis
Clots were formed in re-calcified whole blood samples containing 210 pM tPA (Genentech) using the EXTEM reagent and monitored by rotational thromboelastometry (ROTEM®, Tem International GmbH, Munchen, Germany), in the presence or absence of 1-10 µg/ml PTCI, 25-100 µg/mL recombinant activated FVII (rFVIIa; NovoNordisk, Bagsværd, Denmark) or 0.25-0.75 U/mL activated prothrombin complex concentrate (aPCC; Baxalta, Bannockburn, IL). Data are expressed as means ± SEM and were analysed by two way ANOVA with Dunnett’s post hoc test.

RESULTS and DISCUSSION
The study cases were males aged 59 and 34 years (I.1 and II.2; Figure 1A) with a lifelong propensity for muscle and joint bleeding after minor trauma. Treatment of bleeding with plasma or Factor IX infusions was ineffective. However, single 90 µg/Kg infusions of rFVIIa (NovoNordisk) were usually sufficient to resolve bleeding. Analysis of plasma by CAT showed that compared to healthy controls, the cases had reduced endogenous thrombin potential (ETP; 316.3 ± 51.5 nM/min (n=10) vs 1584.9 ± 56.2 nM/min in controls (n=20); P<0.01) and reduced peak thrombin concentration (71.7 ± 12.5 nM (n=10) vs 273.7 ± 19.6 nM in controls (n=20); P<0.01; Figure 1B, C). Cases and controls showed similar lag time and time to peak thrombin. The plasma TM concentration in the cases was 640.7 ± 21.2 ng/ml (n=4; reference interval 2.9-7.6 ng/ml). No other abnormalities were observed in coagulation factor or anticoagulant protein levels (Supplementary Table S1).
Consistent with this phenotype, both cases had heterozygous c.1611C>A transversions in the major THBD transcript NM_000361.2 which segregated in the pedigree with abnormal bleeding. This predicted p.Cys537Stop in the TM transmembrane domain, an identical variant to the two previously reported TM-AC pedigrees (Figure 1A)6,7. Addition of sTM to control plasma caused dose dependent reductions in ETP and peak thrombin, that with 500 ng/ml sTM were similar to the cases (Figure 1C, D). This indicated a causal relationship between high plasma TM levels in the TM-AC cases and reduced thrombin generation. Addition of the bypassing agents rFVIIa or aPCC, which enhance thrombin generation in other coagulopathies, increased ETP in high-TM model plasma, similar to that in pooled FVIII-deficient control plasma samples (P<0.01 for ETP with 2-100 µg/ml rFVIIa or 0.25-0.75 U/ml aPCC vs ETP with no bypassing agent). Restoration of ETP was less than in the TM-AC plasmas (P<0.01 for ETP with 50-100 µg/ml rFVIIa or 0.5-0.75 U/ml aPCC vs ETP with no bypassing agent; Figure 1E, F).

**Fibrinolysis phenotype**

Lysis of TM-AC plasma clots by tPA was significantly slower than controls (time to 50% lysis 175.1 ± 3.4 min (n=6) vs 103.1 ± 3.9 min in controls (n=3); P<0.01), and was reproduced in high-TM model plasma (time to 50% lysis 164.1 ± 8.6 min (n=3); P<0.01; Figure 2A, D). Addition of MA-T12D11, which specifically inhibits thrombin/TM-mediated TAFI activation15, completely abrogated delayed fibrinolysis in the TM-AC and high-TM model plasma samples (Figure 2B, D). Similarly, inclusion of the TAFIa inhibitor PTCI (25 µg/ml) also reduced the delay in fibrinolysis in TM-AC plasma, although did
not completely reduce the 50% lysis time in the high-TM model to control levels (Figure 2C, D).

Clots formed in TM-AC and high-TM model blood samples showed the same maximum clot firmness as controls (Figure 2E and Supplementary table S1), indicating no differences in initial clot viscoelastic strength. However, compared to controls, the time to 90% lysis was significantly delayed in TM-AC blood (time to 90% lysis 56.5 ± 2.3 min (n=7) vs 29.5 ± 3.5 min in controls (n=3); P<0.01) and in high-TM model blood (50.4 ± 2.0 (n=3); P<0.01; Figure 2E, F), indicating delayed fibrinolysis. Addition of PTCI 1-10 µg/ml caused a dose-dependent reduction in the delay in fibrinolysis in TM-AC and high-TM model blood samples (Figure 2E, F), reproducing the effects in plasma. Addition of 25-100 ng/ml rFVIIa or 0.25-0.75 U/ml aPCC, which partially restored thrombin generation in TM-AC and high-TM model samples, did not alter the delayed fibrinolysis in high TM-model blood (Figure 2G).

We confirm that TM-AC is associated with reduced thrombin generation and reveal that delayed fibrinolysis is a component of the TM-AC phenotype using two experimental models. We show further that both phenotypes are a consequence of high plasma TM levels and that the delay in fibrinolysis is TAFIa-mediated, in line with the established role of TM/thrombin in TAFI activation9,10. It is significant that in the presence of high TM levels, enhanced TAFI activation occurred despite reduced thrombin generation and that partial restoration of thrombin generation with rFVIIa or aPCC did not alter the delayed fibrinolysis. This suggests that in TM-AC, TM rather than thrombin is
the main determinant of TAFI activation. Our findings highlight the complex multifactorial role of TM in the regulation of haemostasis and have important implications for the treatment of bleeding in TM-AC.

ACKNOWLEDGEMENTS
The NIHR BioResource-Rare Diseases and the ThromboGenomics sequencing projects are supported by the National Institute for Health Research (NIHR; http://www.nihr.ac.uk). KB is an NIHR academic clinical fellow. SKW is supported by a Medical Research Council (MRC) Clinical Training Fellowship (MR/K023489/1). KS and ET are supported by the NIHR BioResource Rare Diseases. CSW and NJM are supported by the British Heart Foundation (FS/11/2/28579). ADM is supported by the NIHR Bristol Cardiovascular Biomedical Research Unit.

AUTHORSHIP CONTRIBUTIONS
KB performed experiments and co-wrote the manuscript. CSW, MW, CRS and PC performed experiments. SKW and OGC enrolled the study cases and provided the phenotype descriptions. KS and ET designed and performed genetic analyses. NJM designed experiments and co-wrote the manuscript. ADM oversaw the study, designed experiments and co-wrote the manuscript.

We thank Prof Paul Declerck and Prof Ann Gils, University Leuven, Belgium for the kind gift of the MA-T12D11 antibody to TAFI.

DISCLOSURE OF CONFLICTS OF INTEREST
The authors declare no relevant conflicts of interest
REFERENCES


FIGURE LEGENDS

Figure 1: Reduced thrombin generation in the study cases and response to rFVIIa and aPCC.

A. Pedigree of the study cases with traumatic bleeding indicated by the solid symbols and no abnormal bleeding by open symbols. Genotyped cases are indicated as +/- for the heterozygous THBDN p.Cys537Stop variant and +/+ for reference sequence. Plasma thrombomodulin (TM) concentrations are indicated beneath each pedigree symbol. B. A representative thrombin generation curve from case II.2 in re-calculated plasma collected into 0.106 mM trisodium citrate, following activation with 1 pM tissue factor. The gray shading represents the limits of thrombin generation curves observed in 20 healthy controls. C-D. Plasma endogenous thrombin potential (ETP) peak thrombin concentration from cases I.1 and II.1 (n=10) with thrombomodulin-associated coagulopathy (TM-AC) and in plasma from 20 healthy controls in the absence or presence of recombinant C-terminal truncated human TM (sTM; 250-2500 ng/ml; high-TM model plasma). E-F. ETP in plasma from cases I.1 and II.1 and in high-TM model plasma containing 500 ng/ml sTM and either 25-100 µg/mL recombinant activated FVII (rFVIIa) or 0.25-0.75 U/mL activated prothrombin complex concentrate (aPCC). Statistical comparisons are between ETP values in the presence of the stated concentration of bypassing agent vs ETP in the corresponding sample with no added bypassing agent. The gray boxes indicates the range of ETP observed in 20 healthy control plasmas without addition of sTM. Data are means ± SEM; ** p ≤0.01, NS = not significant.
**Figure 2: Plasma and whole blood fibrinolysis**

**A-C.** Turbidity measured in triplicate at 405 nm in plasma from thrombomodulin-associated coagulopathy (TM-AC) cases I.1 and II.1 (n=6), high-TM model plasma containing 500 ng/ml recombinant C-terminal truncated human TM (sTM; n=3), or control plasma without added sTM (n=3) diluted 30:70 in TBST buffer (10 mM Tris, 140 mM NaCl, 0.01% Tween-20, pH7.4) containing 16 mM phospholipids. Clotting was initiated with 0.1 U/ml thrombin and 10.6 mM CaCl$_2$ in the presence of 300 pM recombinant human tissue plasminogen activator. The curves represent mean turbidity with no carboxypeptidase inhibitor (no CPI), with 65 µg/ml MA-T12D11 or 25 µg/ml PTCI. **D.** Time to 50% clot lysis in the TM-AC (n=6), high-TM model (n=3) and control (n=3) plasma samples in the absence or presence of 65 µg/ml MA-T12D11 or 25 µg/ml PTCI. **E.** Representative ROTEM viscoelastometry traces following clot formation with the EXTEM reagent in whole blood from a healthy control and from TM-AC case II.2. Traces are shown in the absence and presence of 5 µg/ml PTCI. **F.** Time to 90% clot lysis in TM-AC (n=6), high-TM model (n=3) and healthy control (n=20) blood in the absence or presence of 1-10 µg/ml PTCI. **G-H.** Time to 90% clot lysis in high TM-model blood samples in the absence or presence of 25-100 µg/ml recombinant activated FVII (rFVIIa) or 0.25-0.75 U/ml activated prothrombin complex concentrate (aPCC) n=3). Data are means ± SEM; ** p ≤0.01, NS = not significant.
Figure 2

A. No CPI
- Controls
- High-TM model
- TM-AC

B. MA-T12D11
- Controls
- High-TM model
- TM-AC

C. PTCI
- Controls
- High-TM model
- TM-AC

D. Time to 50% lysis (min)
- No CPI
- MA-T12D11
- PTCI

E. Control – no PTCI
- Time (min)
- mm

F. Time to 90% lysis (min)
- PTCI µg/ml

G. Time to 90% lysis (min)
- rFVIIa (µg/ml)
- aPCC (U/ml)

Control WB + 500ng/ml sTM
Supplementary table S1: Coagulation laboratory test results levels from the study cases I.1 and II.2 with thrombomodulin-associated coagulopathy.

<table>
<thead>
<tr>
<th></th>
<th>Reference range</th>
<th>I.1</th>
<th>II.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT (s)</td>
<td>9.5 - 12.0</td>
<td>10.3</td>
<td>10.7</td>
</tr>
<tr>
<td>APTT (s)</td>
<td>23.0 - 32.0</td>
<td>25.3</td>
<td>26.3</td>
</tr>
<tr>
<td>Claus fibrinogen (g/l)</td>
<td>1.5 - 4.0</td>
<td>2.1</td>
<td>2.06</td>
</tr>
<tr>
<td>VWF:Ag (IU/ml)</td>
<td>0.5 - 2.0</td>
<td>1.12</td>
<td>1.05</td>
</tr>
<tr>
<td>VWF:RCo (IU/ml)</td>
<td>0.5 - 2.0</td>
<td>0.85</td>
<td>0.93</td>
</tr>
<tr>
<td>FIX:C (IU/ml)</td>
<td>0.5 - 2.0</td>
<td>0.98</td>
<td>1.06</td>
</tr>
<tr>
<td>FVIII:C (IU/ml)</td>
<td>0.5 - 2.0</td>
<td>1.44</td>
<td>1.08</td>
</tr>
<tr>
<td>FXI:C (IU/ml)</td>
<td>0.7 - 2.0</td>
<td>1.02</td>
<td>0.94</td>
</tr>
<tr>
<td>Free protein S antigen (IU/ml)</td>
<td>0.64 - 1.31</td>
<td>1.19</td>
<td>1.55</td>
</tr>
<tr>
<td>Protein C activity (IU/ml)</td>
<td>0.7 - 1.4</td>
<td>1.06</td>
<td>0.97</td>
</tr>
<tr>
<td>Factor V Leiden genotype</td>
<td>-</td>
<td>Reference sequence</td>
<td>Reference sequence</td>
</tr>
<tr>
<td>Plasminogen activity (%)</td>
<td>75 - 140</td>
<td>122</td>
<td>105</td>
</tr>
<tr>
<td>Endogenous thrombin potential (nM/min)</td>
<td>1092.4 - 2077.4</td>
<td>81.9 ± 10.3*</td>
<td>428.2 ± 20.1*</td>
</tr>
<tr>
<td>Peak thrombin concentration (nM)</td>
<td>101.7 - 445.7</td>
<td>15.4 ± 2.6*</td>
<td>100.8 ± 6.7*</td>
</tr>
<tr>
<td>Lag time (s)</td>
<td>2.8 - 6.8</td>
<td>4.1 ± 0.5*</td>
<td>4.3 ± 0*</td>
</tr>
<tr>
<td>Time to peak thrombin (s)</td>
<td>4.5 - 11.6</td>
<td>9.3 ± 0.2*</td>
<td>6.4 ± 0.2*</td>
</tr>
<tr>
<td>ROTEM clot time (s)</td>
<td>62.4 - 70.2</td>
<td>67.3 ± 1.1*</td>
<td>65.5 ± 0.9*</td>
</tr>
<tr>
<td>ROTEM alpha angle (°)</td>
<td>70.2 - 75.0</td>
<td>72.6 ± 0.3*</td>
<td>71.0 ± 0.4*</td>
</tr>
<tr>
<td>ROTEM maximum clot firmness (mm)</td>
<td>48.4 - 61.1</td>
<td>58.1 ± 1.0*</td>
<td>60.25 ± 0.6*</td>
</tr>
<tr>
<td>ROTEM time to 90% clot lysis (min)</td>
<td>22.7 - 36.3</td>
<td>58.8 ± 4.3*</td>
<td>55.1 ± 2.1*</td>
</tr>
<tr>
<td>ROTEM % clot lysis at 30 minutes (LY 30)</td>
<td>1.8 - 8.5</td>
<td>93.5 ± 2.1*</td>
<td>97.5 ± 1.0*</td>
</tr>
<tr>
<td>ROTEM % clot lysis at 60 minutes (LY 60)</td>
<td>1.8 - 6.2</td>
<td>4.5 ± 0.84*</td>
<td>7.0 ± 1.4*</td>
</tr>
</tbody>
</table>

Analyses were performed using a CS-21000i coagulometer (Sysmex AG, Horgen, Switzerland) using Siemens reagents, a Fluoroscan Ascent fluorimeter (Thermo-Fischer, Basingstoke, UK) and a ROTEM rotational viscoelastometer (Haemonetics, Braintree, MA) according to the manufacturers instructions using venous blood samples collected into 0.106 mM trisodium citrate. Coagulation assays for FVIII:C, FXI:C and FXI: C were one-stage APTT based assays. VWF:Ag was measured using the VWFAg immunoturbidimetric reagent and VWF:Rco using the BC VWF RCof activity kit. Protein C activity was determined using the Chromogenic PC activity kit and free protein S antigen with the Innovance free protein S kit. Plasminogen activity was determined using the Berichrom Plasminogen kit. *indicates mean± SEM for the results of replicate measurements (n=4-10) for patient (n=4-10) and model samples or healthy controls (n=20).